Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

APARNA TAMIRISA

Allopathic & Osteopathic Physicians Internal Medicine

NPI
1124273974
CMS profile
6084
Location
SUGAR LAND, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$1,000.48

51 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $1,000.48 51

By paying entity

PY2025 · entire year · sorted by reported total

Page 1 of 2; records 1–50 of 51 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

APARNA TAMIRISA

NPI 1124273974 · CMS profile ID 6084

Allopathic & Osteopathic Physicians / Internal Medicine

SUGAR LAND, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 2; records 1–50 of 51 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1124273974?year=2025&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
APARNA TAMIRISA, NPI 1124273974, CMS profile ID 6084. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 2; records 1–50 of 51 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1124273974?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). APARNA TAMIRISA, NPI 1124273974, CMS profile ID 6084. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 2; records 1–50 of 51 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1124273974?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
APARNA TAMIRISA, NPI 1124273974, CMS profile ID 6084, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 2; records 1–50 of 51 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1124273974?year=2025&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

51 matching records · $1,000.48 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 51 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–50 of 51.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Sumitomo Pharma America, Inc. $20.7012/18/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1176727013 CMS
Otsuka America Pharmaceutical, Inc. $19.8812/16/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1227511616 CMS
Dexcom, Inc. $24.3012/04/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1250471160 CMS
Novo Nordisk Inc $22.1412/03/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1188657757 CMS
Abbott Laboratories $22.7911/27/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1240996088 CMS
Lundbeck LLC $17.5411/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1251852229 CMS
Dexcom, Inc. $24.0611/04/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1250471158 CMS
Novo Nordisk Inc $20.4910/30/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1188754564 CMS
Corcept Therapeutics $22.2910/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1214178325 CMS
Sumitomo Pharma America, Inc. $15.7110/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1176727011 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $18.0809/25/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1222991466 CMS
Astellas Pharma US Inc $17.4709/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238673711 CMS
Dexcom, Inc. $20.5609/18/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1250471156 CMS
Corcept Therapeutics $21.7509/16/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1214178303 CMS
ABBVIE INC. $25.2009/09/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1204475925 CMS
Esperion Therapeutics, Inc. $17.5009/09/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1243977163 CMS
Lilly USA, LLC $14.0509/04/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186523473 CMS
Amgen Inc. $17.5609/02/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1228661227 CMS
Bayer Healthcare Pharmaceuticals Inc. $17.7508/19/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1225838762 CMS
Novo Nordisk Inc $22.7208/18/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1188780915 CMS
Novo Nordisk Inc $15.4008/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1189114416 CMS
Sumitomo Pharma America, Inc. $17.0207/30/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1176727009 CMS
Lilly USA, LLC $24.8207/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186524181 CMS
Dexcom, Inc. $25.8107/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1250471154 CMS
Amgen Inc. $15.1906/26/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1228661235 CMS
Lilly USA, LLC $24.9906/26/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186473611 CMS
Sumitomo Pharma America, Inc. $14.6306/25/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1176727007 CMS
Bayer Healthcare Pharmaceuticals Inc. $18.2606/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1225838757 CMS
Novo Nordisk Inc $6.1406/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1188515893 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $18.6906/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1222991464 CMS
Amgen Inc. $19.2505/30/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1228661229 CMS
Esperion Therapeutics, Inc. $15.6505/27/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1243977161 CMS
Dexcom, Inc. $25.3805/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1250471152 CMS
Lilly USA, LLC $25.1405/16/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186524179 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $29.7105/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1222991462 CMS
Exact Sciences Corporation $24.9704/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1235445797 CMS
Novo Nordisk Inc $13.9804/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1188921055 CMS
PFIZER INC. $23.8203/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1229152622 CMS
Novo Nordisk Inc $19.8603/27/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1189060718 CMS
AstraZeneca Pharmaceuticals LP $16.7503/25/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206929520 CMS
Dexcom, Inc. $30.3603/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1250471150 CMS
Novo Nordisk Inc $12.6903/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1188615641 CMS
AstraZeneca Pharmaceuticals LP $17.3403/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206766310 CMS
Novo Nordisk Inc $17.3003/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1189064133 CMS
Novo Nordisk Inc $23.8202/27/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1188744480 CMS
Medtronic, Inc. $17.3102/25/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1219927360 CMS
Bayer Healthcare Pharmaceuticals Inc. $17.1002/18/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1225838759 CMS
Amgen Inc. $24.2402/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1228661231 CMS
Novo Nordisk Inc $6.7502/05/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1188985251 CMS
Amgen Inc. $17.2401/23/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1228661233 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $82.95 5
PY2020 $241.91 14
PY2021 $436.11 29
PY2022 $964.56 53
PY2023 $844.80 53
PY2024 $738.71 36
PY2025 $1,000.48 51

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $417,693.13 33
PY2024 Principal investigator $337,941.60 29
PY2023 Principal investigator $114,419.07 43
PY2022 Principal investigator $112,985.59 129
PY2021 Principal investigator $135,746.11 40
PY2020 Principal investigator $314,454.61 68
PY2019 Principal investigator $340,052.76 93

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

40 records in PY2021

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Novo Nordisk AS $1,238.63 12/22/2021 Non-covered Recipient Entity
HOUSTON CENTER FOR CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 810848015
Principal investigator 1 ABBVIE INC. $1,228.78 12/02/2021 Non-covered Recipient Entity
HOUSTON CENTER FOR CLINICAL RESEARCH
A Phase 3b Study to Evaluate the Long-Term Safety of Elagolix in Combination with Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated with Uterine Fibroids in Premenopausal Women No dispute reported 06/30/2026 792485001
Principal investigator 1 ABBVIE INC. $6,350.02 11/10/2021 Non-covered Recipient Entity
HOUSTON CENTER FOR CLINICAL RESEARCH
A Phase 3b Study to Evaluate the Long-Term Safety of Elagolix in Combination with Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated with Uterine Fibroids in Premenopausal Women No dispute reported 06/30/2026 792482393
Principal investigator 1 Novo Nordisk AS $1,238.63 10/29/2021 Non-covered Recipient Entity
HOUSTON CENTER FOR CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 811374056
Principal investigator 1 Myovant Sciences Inc. $6,450.00 10/13/2021 Non-covered Recipient Entity
HOUSTON CTR FOR CLINICAL RESEARCH
SPIRIT 2: AN INTERNATIONAL PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED EFFICACY AND SAFETY STUDY TO EVALUATE RELUGOLIX ADMINISTERED WITH AND WITHOUT LOW-DOSE ESTRADIOL AND NORETHINDRONE ACETATE IN WOMEN WITH ENDOMETRIOSIS-ASSOCIATED PAIN No dispute reported 06/30/2026 835053673
Principal investigator 1 ABBVIE INC. $8,079.01 10/07/2021 Non-covered Recipient Entity
HOUSTON CENTER FOR CLINICAL RESEARCH
A Phase 3b Study to Evaluate the Long-Term Safety of Elagolix in Combination with Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated with Uterine Fibroids in Premenopausal Women No dispute reported 06/30/2026 792478495
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $21,641.88 10/05/2021 Non-covered Recipient Entity
Interspond - Houston Center For Clinical Research
A Multi-Center, Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Phase 3 Study With Randomized Withdrawal and Retreatment to Evaluate the Efficacy and Safety of BMS-986165 in Subjects With Moderate-to-Severe Plaque Psoriasis No dispute reported 06/30/2026 819895367
Principal investigator 1 Novo Nordisk AS $1,850.63 09/24/2021 Non-covered Recipient Entity
HOUSTON CENTER FOR CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 811556595
Principal investigator 1 Myovant Sciences GmbH $5,500.00 09/02/2021 Non-covered Recipient Entity
HOUSTON CENTER FOR CLINICAL RESEARCH LLC
A PHASE 3 SINGLEARM OPENLABEL STUDY TO EVALUATE THE CONTRACEPTIVE EFFICACY OF RELUGOLIX COMBINATION THERAPY IN HEALTHY WOMEN 18 TO 35 YEARS OF AGE WHO ARE AT RISK FOR PREGNANCY No dispute reported 06/30/2026 835052553
Principal investigator 1 Myovant Sciences GmbH $1,500.00 09/02/2021 Non-covered Recipient Entity
HOUSTON CENTER FOR CLINICAL RESEARCH LLC
A PHASE 3 SINGLEARM OPENLABEL STUDY TO EVALUATE THE CONTRACEPTIVE EFFICACY OF RELUGOLIX COMBINATION THERAPY IN HEALTHY WOMEN 18 TO 35 YEARS OF AGE WHO ARE AT RISK FOR PREGNANCY No dispute reported 06/30/2026 835052555
Principal investigator 1 ABBVIE INC. $1,949.28 08/30/2021 Non-covered Recipient Entity
HOUSTON CENTER FOR CLINICAL RESEARCH
A Phase 3b Study to Evaluate the Long-Term Safety of Elagolix in Combination with Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated with Uterine Fibroids in Premenopausal Women No dispute reported 06/30/2026 792473113
Principal investigator 1 Novo Nordisk AS $405.00 08/30/2021 Non-covered Recipient Entity
HOUSTON CENTER FOR CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 811556577
Principal investigator 1 ABBVIE INC. $7,680.43 07/29/2021 Non-covered Recipient Entity
HOUSTON CENTER FOR CLINICAL RESEARCH
A Phase 3b Study to Evaluate the Long-Term Safety of Elagolix in Combination with Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated with Uterine Fibroids in Premenopausal Women No dispute reported 06/30/2026 792469961
Principal investigator 1 Novo Nordisk AS $1,328.63 07/28/2021 Non-covered Recipient Entity
HOUSTON CENTER FOR CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 810731081
Principal investigator 1 ABBVIE INC. $2,890.08 06/30/2021 Non-covered Recipient Entity
HOUSTON CENTER FOR CLINICAL RESEARCH
A Phase 3b Study to Evaluate the Long-Term Safety of Elagolix in Combination with Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated with Uterine Fibroids in Premenopausal Women No dispute reported 06/30/2026 792464997
Principal investigator 1 Novo Nordisk AS $2,040.20 06/28/2021 Non-covered Recipient Entity
HOUSTON CENTER FOR CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 810848035
Principal investigator 1 Novo Nordisk AS $720.57 05/28/2021 Non-covered Recipient Entity
HOUSTON CENTER FOR CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 810731099
Principal investigator 1 ABBVIE INC. $702.16 05/27/2021 Non-covered Recipient Entity
HOUSTON CENTER FOR CLINICAL RESEARCH
A Phase 3b Study to Evaluate the Long-Term Safety of Elagolix in Combination with Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated with Uterine Fibroids in Premenopausal Women No dispute reported 06/30/2026 792460599
Principal investigator 1 ABBVIE INC. $8,348.13 04/29/2021 Non-covered Recipient Entity
HOUSTON CENTER FOR CLINICAL RESEARCH
A Phase 3b Study to Evaluate the Long-Term Safety of Elagolix in Combination with Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated with Uterine Fibroids in Premenopausal Women No dispute reported 06/30/2026 792449649
Principal investigator 1 Novo Nordisk AS $1,294.88 04/26/2021 Non-covered Recipient Entity
HOUSTON CENTER FOR CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 810731091
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $4,894.00 04/22/2021 Non-covered Recipient Entity
Houston Center For Clinical Research Llc
BAY94-8862 ph 3 conventional in diabetic nephropathy No dispute reported 06/30/2026 789142905
Principal investigator 1 ABBVIE INC. $4,340.25 03/30/2021 Non-covered Recipient Entity
HOUSTON CENTER FOR CLINICAL RESEARCH
A Phase 3b Study to Evaluate the Long-Term Safety of Elagolix in Combination with Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated with Uterine Fibroids in Premenopausal Women No dispute reported 06/30/2026 792437667
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $3,500.00 03/24/2021 Non-covered Recipient Entity
Houston Center For Clinical Research Llc
Assess efficacyand safetyof three different doses of P2X3 antagonist in women with symptomatic endometriosis No dispute reported 06/30/2026 789126411
Principal investigator 1 Novo Nordisk AS $2,229.20 03/24/2021 Non-covered Recipient Entity
HOUSTON CENTER FOR CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 811374065
Principal investigator 1 Novo Nordisk AS $250.00 03/24/2021 Non-covered Recipient Entity
HOUSTON CENTER FOR CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 811556613
Principal investigator 1 ABBVIE INC. $3,083.67 03/02/2021 Non-covered Recipient Entity
HOUSTON CENTER FOR CLINICAL RESEARCH
A Phase 3b Study to Evaluate the Long-Term Safety of Elagolix in Combination with Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated with Uterine Fibroids in Premenopausal Women No dispute reported 06/30/2026 792428857
Principal investigator 1 Novo Nordisk AS $675.57 02/22/2021 Non-covered Recipient Entity
HOUSTON CENTER FOR CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 810848025
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $512.00 02/10/2021 Non-covered Recipient Entity
Houston Center For Clinical Research Llc
BAY94-8862 ph 3 conventional in diabetic nephropathy No dispute reported 06/30/2026 789141335
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $512.00 02/10/2021 Non-covered Recipient Entity
Houston Center For Clinical Research Llc
BAY94-8862 ph 3 conventional in diabetic nephropathy No dispute reported 06/30/2026 789144831
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $8,936.82 02/09/2021 Non-covered Recipient Entity
Interspond - Houston Center For Clinical Research
Long-Term Study That Measures the Safety and Efficacy of BMS-986165 in Participants With Psoriasis No dispute reported 06/30/2026 819895373
Principal investigator 1 ABBVIE INC. $8,078.56 01/28/2021 Non-covered Recipient Entity
HOUSTON CENTER FOR CLINICAL RESEARCH
A Phase 3b Study to Evaluate the Long-Term Safety of Elagolix in Combination with Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated with Uterine Fibroids in Premenopausal Women No dispute reported 06/30/2026 792415247
Principal investigator 1 Novo Nordisk AS $4,780.71 01/28/2021 Non-covered Recipient Entity
HOUSTON CENTER FOR CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 811374047
Principal investigator 1 Novo Nordisk AS $200.00 01/28/2021 Non-covered Recipient Entity
HOUSTON CENTER FOR CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 811556603
Principal investigator 1 Myovant Sciences Inc. $692.55 01/18/2021 Non-covered Recipient Entity
HOUSTON CTR FOR CLINICAL RESEARCH
SPIRIT EXTENSION: AN INTERNATIONAL PHASE 3 OPEN-LABEL, SINGLE-ARM, SAFETY AND EFFICACY EXTENSION STUDY TO EVALUATE RELUGOLIX ADMINISTERED WITH LOW-DOSE ESTRADIOL AND NORETHINDRONE ACETATE IN WOMEN WITH ENDOMETRIOSIS-ASSOCIATED PAIN No dispute reported 06/30/2026 835052787
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $2,022.00 01/15/2021 Non-covered Recipient Entity
Houston Center For Clinical Research Llc
BAY94-8862 ph 3 conventional in diabetic nephropathy No dispute reported 06/30/2026 789140413
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $2,534.00 01/15/2021 Non-covered Recipient Entity
Houston Center For Clinical Research Llc
BAY94-8862 ph 3 conventional in diabetic nephropathy No dispute reported 06/30/2026 789142133
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $3,504.00 01/15/2021 Non-covered Recipient Entity
Houston Center For Clinical Research Llc
BAY94-8862 ph 3 conventional in diabetic nephropathy No dispute reported 06/30/2026 789143625
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $512.00 01/15/2021 Non-covered Recipient Entity
Houston Center For Clinical Research Llc
BAY94-8862 ph 3 conventional in diabetic nephropathy No dispute reported 06/30/2026 789144275
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $2,022.00 01/15/2021 Non-covered Recipient Entity
Houston Center For Clinical Research Llc
BAY94-8862 ph 3 conventional in diabetic nephropathy No dispute reported 06/30/2026 789145433
Principal investigator 1 Novartis Pharmaceuticals Corporation $29.84 01/15/2021 Non-covered Recipient Entity
HOUSTON CENTER FOR CLINICAL RESEARCH
MULTICENTER RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED 52 WEEK STUDY TO DEMONSTRATE THE EFFICACY SAFETY AND TOLERABILITY OF SECUKINUMAB INJECTIONS WITH 2 ML AUTO INJECTORS 300 MG IN ADULT SUBJECTS WITH PLAQUE PSORIASIS No dispute reported 06/30/2026 800632807